Patrys FY21 Annual Report

ASX Announcements

Patrys has today released its Annual Report for the 2020-2021 Financial Year (FY21).

Highlights include:


  • Expansion of deoxymab portfolio with the addition of full sized IgG antibody, PAT-DX3
  • First patent granted for deoxymab-nanoparticles
  • Capital raising of $7.3m via a Placement and Rights Issue


  • Successful development and selection of an optimised stable cell-line for commercial scale production of clinical grade PAT-DX1
  • New United States patent granted for Patrys’ deoxymab assets
  • Completion of animal pharmacokinetic studies for both PAT-DX1 antibody fragment and full-sized PAT-DX3 IgG antibody
  • Announcement of a collaborative research program with Imagion Biosystems Limited to improve brain tumor imaging and diagnosis
  • Publication of preclinical data, from collaboration with Yale School of Medicine demonstrating the ability of PAT-DX1 to cross the blood-brain barrier (BBB) and significantly inhibit the growth of both primary and secondary cancers in the brain in animal models

Click here to read the full report.